<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26514584</article-id>
<article-id pub-id-type="pmc">4869040</article-id>
<article-id pub-id-type="pii">npp2015335</article-id>
<article-id pub-id-type="doi">10.1038/npp.2015.335</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse</article-title>
<alt-title alt-title-type="running">SERT dependency of SSRI actions</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Nackenoff</surname>
<given-names>Alex G</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Moussa-Tooks</surname>
<given-names>Alexandra B</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6778-8379</contrib-id>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McMeekin</surname>
<given-names>Austin M</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Veenstra-VanderWeele</surname>
<given-names>Jeremy</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Blakely</surname>
<given-names>Randy D</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Department of Pharmacology, Vanderbilt University School of Medicine</institution>, Nashville, TN, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Psychiatry, Vanderbilt University School of Medicine</institution>, Nashville, TN, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Psychiatry, Columbia University College of Physicians and Surgeons/New York Psychiatric Institute</institution>, New York, NY, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Department of Pharmacology, Vanderbilt University School of Medicine</institution>, 7140 MRBIII, PMB 407933, Nashville, TN 37240-7933, <country>USA</country>, Tel: +615 936 1700, Fax: +615 936 3745, E-mail: <email>randy.blakely@vanderbilt.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epreprint">
<day>30</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>25</day>
<month>11</month>
<year>2015</year>
</pub-date>
<volume>41</volume>
<issue>7</issue>
<fpage>1733</fpage>
<lpage>1741</lpage>
<history>
<date date-type="received">
<day>07</day>
<month>09</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>20</day>
<month>10</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>27</day>
<month>10</month>
<year>2015</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright Â© 2016 American College of Neuropsychopharmacology</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>American College of Neuropsychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>Depression is a common mental illness and a leading cause of disability. The most widely prescribed antidepressant medications are serotonin (5-HT) selective reuptake inhibitors (SSRIs). Although there is much support for 5-HT transporter (SERT) antagonism as a basis of antidepressant efficacy, this evidence is indirect and other targets and mechanisms have been proposed. In order to distinguish SERT-dependent and -independent effects of SSRIs, we developed a knock-in mouse model whereby high-affinity interactions of many antidepressants at SERT have been ablated via knock-in substitution (SERT Met172) without disrupting 5-HT recognition or uptake. Here we utilize the C57BL/6J SERT Met172 model to evaluate SERT dependence for the actions of two widely prescribed SSRIs, fluoxetine and citalopram, in tests sensitive to acute and chronic actions of antidepressants. In the tail suspension and forced swim tests, fluoxetine and citalopram fail to reduce immobility in SERT Met172 mice. In addition, SERT Met172 mice are insensitive to chronic fluoxetine and citalopram administration in the novelty induced hypophagia test (NIH) and fail to exhibit enhanced proliferation or survival of hippocampal stem cells. In both acute and chronic studies, SERT Met172 mice maintained sensitivity to paroxetine, an antidepressant that is unaffected by the Met172 mutation. Together, these studies provide definitive support for an essential role of SERT antagonism in the acute and chronic actions of two commonly used SSRIs in these tests, and reinforce the utility of the SERT Met172 model for isolating SERT/5-HT contributions of drug actions <italic>in vivo</italic>.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>